华融化学股份有限公司 董事会提名委员会工作制度 第一章 总 则 第一条 为规范华融化学股份有限公司（以下简称"公司"）领导人员的 产生，优化董事会和高级管理层的组成，完善公司治理结构，根据《中华人民共 和国公司法》等有关法律、法规、规范性文件及《华融化学股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，公司特设立董事会提名委员会，并制 订本制度。 第二条 提名委员会是董事会设立的专门工作机构。主要负责对公司董事 和高级管理人员的人选、选择标准和程序进行选择并提出建议。 第二章 人员组成 第三条 提名委员会由3名董事组成，独立董事应当过半数并担任召集 人。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事 的三分之一以上提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担任， 负责主持委员会工作；主任委员（召集人）在委员内选举，并报请董事会批准产 生。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任董事职务，即自动失去委员资格，并由董事会根据上 述第三条至第五条规定补足委员人数。 第三章 职责权限和决策程序 ...

华融化学股份有限公司（以下简称"公司"）根据《企业会计准则》及《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关规定，对公司 2023 年上半年度（以下简称"报告期"）合并财务报表范围内 相关资产计提减值损失。现将具体情况公告如下： 一、本次计提资产减值损失和信用减值损失情况概述 为真实、公允、准确地反映公司截至 2023 年 6 月 30 日的资产和财务状况， 本着谨慎性原则，公司根据《企业会计准则》、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及公司会计政策的相关规定，对 合并范围内的各类资产进行全面清查，并进行充分的评估和分析，对各项可能发 生资产减值损失的相关资产计提了减值损失。 证券代码：301256 证券简称：华融化学 公告编号：2023-060 华融化学股份有限公司 关于 2023 年半年度计提资产减值损失和 信用减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《深圳证劵交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公 ...

根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《华融化学股份有限公司章程》《华融化学 股份有限公司独立董事工作制度》等有关规定，我们作为华融化学股份有限公司 华融化学股份有限公司 独立董事对公司第二届董事会第三次会议相关事项的独立意见 情况不存在重大差异。公司董事会编制的《2023 年半年度募集资金存放与使用情 况的专项报告》内容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗 漏。 （以下无正文） （本页无正文，为《华融化学股份有限公司独立董事对公司第二届董事会第三次 会议相关事项的独立意见》之签署页） 独立董事（签字）： 姚宁 （以下称"公司"）独立董事，就公司第二届董事会第三次会议审议的有关议案， 在查阅公司提供的相关资料、了解相关情况后，基于独立判断的立场，发表独立 意见如下： 一、关于控股股东及其他关联方占用公司资金、公司对外担保等情况的专项 说明和独立意见 根据《上市公司独立董事规则》、《上市公司监管指引第 8 号——上市公司 资金往来、对外担保的监管要求》的要求和《深圳证券交易所创业板上市公司自 律监管指南第 1 号——业务办理》的规 ...

华泰联合证券有限责任公司 关于华融化学股份有限公司 2023年半年度募集资金存放与使用情况的专项核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为华融 化学股份有限公司（以下简称"华融化学"或"公司"或"上市公司"）首次公开发行 股票并在创业板上市（以下简称"本次发行"）之保荐机构，根据《证券发行上市 保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管理和使用 的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等规定，对公司 2023 年半 年度募集资金存放与使用情况进行了认真、审慎的核查，具体核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经深圳证券交易所核准并经中国证券监督管理委员会注册（证监许可〔2022〕 252 号），公司首次公开发行人民币普通股 12,000 万股，每股发行价格人民币 8.05 元，募集资金总额 966,000,000.00 元，扣除各项发行费用（不含税）人民币 64,577,748.25 元,实际募集资金净额为人民币 901,422,25 ...

华融化学股份有限公司 董事会秘书工作制度 第一条 为规范公司运作，根据《中华人民共和国公司法》（下称"《公司 法》"）等有关法律、法规、规范性文件及《华融化学股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，并结合公司实际情况，制订本制度。 第二条 董事会设董事会秘书，董事会秘书由董事长提名，董事会聘任或 解聘，对董事会负责。 第三条 董事会秘书应当具备履行职责所必需的财务、管理、法律等专业 知识，具有良好的职业道德和个人品质，并取得国内证券交易所规定的董事会秘 书任职资格。具有下列情形之一的人士不得担任公司董事会秘书： （一） 《公司法》第 146 条规定的任何一种情形； （二） 最近三年受到过中国证监会的行政处罚； （三） 最近三年受到过交易所公开谴责或三次以上通报批评； （四） 公司现任监事； （五） 公司上市的证券交易所认定不适合担任董事会秘书的其他情形； （六） 法律、行政法规或部门规章规定的其他情形。 第四条 董事会秘书的主要职责： （九） 促使董事会、高级管理人员依法行使职权； （十） 《公司法》、《证券法》、中国证监会和证券交易所要求履行的其 他职责。 第五条 公司应为董事会秘书履行 ...

Financial Performance - The company's revenue for Q1 2023 was ¥271,112,684.09, representing a 67.80% increase compared to ¥161,564,904.21 in the same period last year[5] - Net profit attributable to shareholders was ¥36,919,134.34, a significant increase of 486.13% from ¥6,298,759.91 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥28,715,792.15, up 537.52% from ¥4,504,304.21 in the previous year[5] - Basic and diluted earnings per share increased to ¥0.08, a 300.00% rise from ¥0.02 in the previous year[5] - Operating profit for Q1 2023 was ¥44,968,114.46, compared to ¥7,446,179.80 in Q1 2022, indicating a substantial improvement[19] - The company reported a net profit of ¥44,968,114.46 for Q1 2023, a significant increase compared to the previous year's profit of ¥7,446,179.80[19] - In Q1 2023, Huarong Chemical reported a net profit of CNY 36,919,134.34, a significant increase from CNY 6,298,759.91 in the same period last year, representing a growth of approximately 484%[20] Cash Flow - The net cash flow from operating activities was ¥7,030,970.34, a turnaround from a negative cash flow of ¥36,640,674.50 in the same period last year, marking a 119.19% improvement[5] - Cash generated from operating activities improved by 119.19% to CNY 7,030,970.34, reflecting increased sales and collections[10] - Total cash inflow from operating activities reached CNY 272,958,845.92, compared to CNY 179,984,641.31 in the previous year, indicating a year-over-year increase of about 51.7%[23] - Cash flow from investing activities was CNY 295,495,911.06, a 288.32% increase due to net recoveries from structured deposits and interest[10] - Cash flow from investment activities showed a net inflow of CNY 295,495,911.06, a turnaround from a net outflow of CNY -156,912,280.50 in the same quarter last year[23] - The company recorded cash and cash equivalents at the end of Q1 2023 amounting to CNY 775,000,596.78, down from CNY 1,009,330,737.93 at the end of Q1 2022[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,152,473,876.91, a decrease of 2.92% from ¥2,217,204,122.53 at the end of the previous year[5] - Total current assets decreased to ¥1,855,748,046.46 from ¥1,925,407,837.28, a decline of 3.6%[16] - Total liabilities decreased to ¥500,805,868.17 from ¥564,118,213.30, a reduction of 11.2%[17] - Non-current assets increased to ¥296,725,830.45 from ¥291,796,285.25, a growth of 1.5%[16] Operational Metrics - The company reported a 102.75% increase in inventory, reaching ¥94,848,494.20, due to increased production and procurement of potassium chloride[9] - Accounts receivable rose by 95.67% to ¥83,662,383.36, driven by increased business volume[9] - The company's operating costs increased by 52.14% to CNY 217,350,614.94 due to higher market demand and sales scale[10] - Total operating costs for Q1 2023 were ¥238,836,595.28, up 54.1% from ¥154,953,925.02 in Q1 2022[19] - Research and development expenses for Q1 2023 were ¥2,269,315.26, slightly down from ¥2,448,279.85 in Q1 2022[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,026[12] - The largest shareholder, New Hope Chemical Investment Co., Ltd., holds 71.63% of the shares, totaling 343,800,000 shares[12] Non-Recurring Gains and Expenses - The company recognized non-recurring gains totaling ¥8,203,342.19, primarily from government subsidies and fair value changes of financial assets[6] - Tax and additional charges rose by 156.68% to CNY 2,577,877.25, primarily due to increased VAT payments[10] - Management expenses surged by 113.47% to CNY 13,476,796.20, attributed to an increase in personnel and related compensation[10] - Financial expenses skyrocketed by 339.73% to CNY 1,679,574.55, mainly due to increased foreign exchange losses[10] - The company reported a significant increase in investment income by 998.53% to CNY 4,344,269.65 from structured deposit returns[10] Miscellaneous - The company plans to continue expanding its market presence and investing in new product development to sustain growth[9] - The company did not undergo an audit for the Q1 2023 report[25]

证券代码： 301256 证券简称：华融化学 华融化学股份有限公司投资者关系活动记录表 2023-001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 公众投资者 | | 人员姓名 | | | 时间 | 2023 年 3 月 20 日（周一） 下午 16:30~18:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长邵军 | | 员姓名 | 2、独立董事姚宁 | | | 3、副总经理、董事会秘书、财务总监张炜 | | | 4、保荐代表人桂程 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、公司 2022 年的经营业绩亮点何在？ | | | 您好，公司 2022 年 3 月成功登陆深交所创业板，全年实现 | | | 营业 ...

证券代码：301256 证券简称：华融化学 公告编号：2023-017 华融化学股份有限公司 关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华融化学股份有限公司（以下简称"公司"）已于 2023 年 2 月 28 日披露《2022 年年度报告》。为了让广大投资者进一步了解公司的生产经营情况和发展战略，公司 将于 2023 年 3 月 20 日（星期一）16:30 至 18:00 举行 2022 年年度网上业绩说明会。 本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动 平台"（https://ir.p5w.net）参与。 出席本次业绩说明会的人员有：公司董事长邵军先生，独立董事姚宁先生，副总 经理、董事会秘书、财务总监张炜先生，保荐代表人桂程先生。 为充分尊重投资者，提升交流的针对性，现就公司本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 3 月 17 日（星期 五）15:00 前访问 http://ir.p5w.net/zj/，或扫描下方 ...

Financial Performance - Huarong Chemical reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year increase of 15%[31]. - The company achieved a net profit of RMB 200 million in 2022, which is a 10% increase compared to the previous year[31]. - The company's operating revenue for 2022 was ¥1,135,008,258.39, representing a 76.14% increase compared to ¥644,384,542.46 in 2021[36]. - The net profit attributable to shareholders for 2022 was ¥122,148,212.10, a 19.90% increase from ¥101,876,191.46 in 2021[36]. - The total cash and cash equivalents increased by 56.96% to ¥276,443,750.95, driven by successful fundraising and bank loans[88]. - The company reported a net profit of CNY 44.52 million for the period, with a revenue of CNY 423.63 million, reflecting a significant contribution from its subsidiary, Huarong Chemical (Chengdu) Co., Ltd.[105]. - The company reported a revenue of 1.5 billion yuan for the fiscal year 2022, representing a year-over-year increase of 15%[130]. - The company has set a performance target for 2023, aiming for a revenue growth of 15% year-over-year[135]. Market Expansion and Strategy - Huarong Chemical plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[31]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[31]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[130]. - Huarong Chemical is focusing on expanding its market presence in Southeast Asia, with plans to increase exports by 20% in the next fiscal year[135]. - The company plans to enter three new provinces in China by the end of 2023, targeting a 5% market share in these regions[130]. Research and Development - The company is committed to enhancing its research and development capabilities for new products and technologies in the fine chemical sector[6]. - The company is investing RMB 100 million in R&D for new product development, focusing on eco-friendly chemical solutions[31]. - The company is focusing on R&D innovation, particularly in the development of G4 and G5 grade electronic hydrochloric acid and increasing production of electronic-grade potassium hydroxide and hydrochloric acid[109]. - The R&D budget for new product development has been increased by 25% in 2022, emphasizing innovation in chemical materials[135]. - The number of R&D personnel increased by 17.50% from 80 in 2021 to 94 in 2022, with a notable rise in the proportion of personnel holding bachelor's degrees to 70.27%[84]. Environmental Compliance and Sustainability - The company emphasizes compliance with environmental regulations, having reported no violations during the reporting period[10]. - Huarong Chemical is committed to sustainability, with plans to reduce carbon emissions by 15% over the next three years[31]. - The company has invested in advanced treatment facilities, such as the chlorine gas alkaline washing tower and the chlorine gas absorption tower, to ensure compliance with emission standards[167]. - Huarong Chemical's overall environmental management practices have resulted in no instances of exceeding discharge limits for key pollutants in the reporting period[166]. - The company has established emergency response plans for environmental incidents as per the regulations effective from September 28, 2010[163]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs[31]. - The company is implementing new technologies to enhance operational efficiency, aiming for a 15% reduction in production costs by 2024[133]. - The production process is highly automated, with a continuous production model in place to ensure efficiency and quality control[53]. - The company has established a circular economy operation model, linking various production sectors and processes to optimize resource utilization[53]. Governance and Management - The company has established a comprehensive governance structure, ensuring clear responsibilities among the shareholders' meeting, board of directors, supervisory board, and senior management, with no significant deficiencies in governance[115]. - The company has conducted several shareholder meetings in 2022, with participation rates of 75.04% for the first extraordinary meeting, 75.01% for the annual meeting, and 75.12% for the third extraordinary meeting[119]. - The company’s board of directors includes experienced professionals with backgrounds in finance and management, enhancing its strategic direction[124]. - The company has established a performance-oriented compensation system to enhance employee motivation and align with market standards[149]. Financial Management and Fundraising - The company raised a total of RMB 966 million through the issuance of 12 million shares at RMB 8.05 per share, with a net amount of RMB 901.42 million after deducting issuance costs[97]. - The company has committed to using the raised funds in compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[97]. - The company will enhance the management of raised funds to improve capital utilization efficiency[182]. - The company has established measures to ensure fair pricing in any necessary related party transactions[183]. Safety and Risk Management - The company acknowledges the risk of safety incidents during production due to operational errors or equipment failures[10]. - The company has a significant focus on safety, with multiple safety production licenses and hazardous chemical operation permits[61]. - The company organized emergency drills every six months and specialized drills quarterly as part of its emergency response plan[168]. Shareholder Relations and Commitments - The company has established a clear policy for reporting shareholdings and changes by its directors and senior management[180]. - The company will ensure compliance with the China Securities Regulatory Commission and Shenzhen Stock Exchange regulations regarding shareholding changes[181]. - The company has committed to transparency regarding any unfulfilled public commitments and will disclose relevant information in its periodic reports[183].

Financial Performance - The company's revenue for Q3 2022 reached ¥365,095,595.66, representing a 187.37% increase year-over-year[5]. - Net profit attributable to shareholders was ¥40,052,611.27, up 104.77% compared to the same period last year[5]. - Operating income for the year-to-date reached ¥801,715,694.16, an 80.69% increase compared to the same period last year[9]. - Total operating revenue for the current period reached ¥801,715,694.16, a significant increase from ¥443,689,774.48 in the previous period, representing an increase of approximately 80.7%[19]. - Net profit for the current period was ¥75,673,586.96, compared to ¥69,386,112.41 in the previous period, indicating an increase of approximately 9.3%[20]. - Basic earnings per share for the period was ¥0.0834, a 53.56% increase year-over-year[5]. - Basic and diluted earnings per share were both reported at ¥0.1577, down from ¥0.1927 in the previous period[20]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,159,715,602.97, reflecting a 175.44% increase from the previous year-end[5]. - Current assets amounted to CNY 1,877,991,507.93, up from CNY 524,332,157.59 at the start of the year, indicating a growth of about 258%[16]. - Total liabilities rose to CNY 552,377,982.14 from CNY 130,021,302.75, marking an increase of approximately 325%[17]. - The company's equity attributable to shareholders increased to CNY 1,607,337,620.83 from CNY 654,069,040.90, reflecting a growth of about 145%[17]. Cash Flow - Cash flow from operating activities generated a net amount of ¥131,748,918.63, a turnaround from a negative cash flow of ¥26,085,255.11 in the previous period[21]. - Cash inflow from investment activities totaled ¥2,035,236,249.61, significantly higher than ¥310,059,894.49 in the previous period[21]. - The company reported a net cash outflow from investment activities of ¥1,144,489,457.56, compared to a smaller outflow of ¥50,531,199.38 in the previous period[21]. - Cash flow from financing activities resulted in a net inflow of ¥1,017,183,756.24, contrasting with a net outflow of ¥10,015,000.00 in the previous period[22]. - The company’s cash and cash equivalents at the end of the period stood at ¥294,680,394.39, up from ¥19,321,302.64 at the end of the previous period[22]. Investments and Receivables - The company reported a significant increase in accounts receivable, which rose by 133.69% to ¥68,132,376.80 due to increased business volume[9]. - The company experienced a 341.81% increase in financing receivables, totaling ¥49,109,713.08, attributed to higher business activity[9]. - The company reported a 471.47% increase in investment income, amounting to ¥12,196,249.61, due to higher returns from structured deposits[9]. Borrowings and Financial Strategy - The company has seen a significant rise in short-term borrowings, which increased by 1,854.58% to ¥150,009,333.33, indicating a strategy to leverage for growth[9]. - Short-term borrowings surged to CNY 150,009,333.33, compared to CNY 7,674,748.24 at the beginning of the year, representing an increase of over 1,900%[17]. Other Financial Metrics - The total number of restricted shares at the end of the period was 360,000,000, with 7,322,657 shares released during the current period[13]. - The company plans to unlock 343,800,000 shares of restricted stock by March 22, 2025, as part of its initial public offering restrictions[13]. - The company has increased its prepayments to CNY 105,221,606.33 from CNY 21,958,564.31, showing a growth of approximately 378%[16]. - Inventory levels were reported at CNY 94,330,547.13, up from CNY 89,225,313.34, indicating a growth of approximately 6%[16]. - The company experienced a decrease in financial expenses, reporting a net financial income of ¥6,689,926.08 compared to an expense of ¥285,227.00 in the previous period[19].